• Mavacamten met the primary endpoint for the treatment of Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy • Mavacamten demonstrated a safety profile consistent with previous studies • If approved, mavacamten is expected to be the first cardiac myosin inhibitor approved in China for the treatment of oHCM • LianBio to host a […]
Other News
Surmodics Reports Second Quarter of Fiscal Year 2023 Financial Results; Updates Fiscal Year 2023 Financial Guidance
EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today reported financial results for its second quarter ended March 31, 2023, and updated its financial guidance for its fiscal year ending September 30, 2023. Second Quarter Fiscal […]
Vektor Medical Welcomes Two New Advisors to Advance Technology and Commercial Development
SAN DIEGO–(BUSINESS WIRE)–Vektor Medical, developer of the vMap® next-generation arrhythmia mapping technology, today announced former Philips and Biotronik medical technology leader Marlou Janssen and Yale Clinical Professor of Medicine and past American College of Cardiology (ACC) Connecticut Chapter Governor and President Dr. Craig McPherson have joined Vektor’s advisory board. With […]
Juniper Research Awards Cardio Diagnostics Holdings, Inc Future Digital Award for Best Digital Diagnostics Solution
List recognizes most innovative and impactful digital health solutions that have the potential to make a significant impact in the future. CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings, Inc (Nasdaq: CDIO), a precision cardiovascular medicine company, today announced its PrecisionCHD™ test received Juniper Research’s Future Digital Award for the “Best Digital Diagnostics Solution.” Juniper Research’s Future […]
egnite Announces Portfolio Expansion to Reduce Stroke Risk in Atrial Fibrillation Patients
Expansion leverages a custom module to help health systems identify patients eligible for lifesaving therapy ALISO VIEJO, Calif.–(BUSINESS WIRE)–egnite, Inc., a leading digital health company for cardiovascular care, announces the expansion of its portfolio with the integration of a custom module designed to help physicians and health systems identify patients […]
Valbiotis announces the release of the Universal Registration Document
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that its Universal Registration Document was filed to the French Financial Markets Regulator (AMF) April 26, […]
FineHeart Granted First Two Patents in China for the FLOWMAKER®
Extending the intellectual property of its fully implantable medical device for restoring cardiac output (ICOMS) BORDEAUX, France–(BUSINESS WIRE)–FineHeart S.A, a medical device company developing the FLOWMAKER®, a fully implantable cardiac output restoration system (ICOMS) to address the unmet needs of patients suffering from severe heart failure, announced today that its first […]
Cardiac Dimensions Receives Medical Device Regulation (MDR) Certification for Carillon Mitral Contour System
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address patients suffering from heart failure with functional mitral regurgitation (FMR), today announced that its Carillon Mitral Contour System® has received certification under Regulation (EU) 2017/745 (“MDR”). The MDR program is intended to ensure high standards […]
Elucid Names Scott Huennekens Executive Chairman of the Board
Proven medtech leader appointed to chair AI-powered cardiovascular technology through commercialization and expansion BOSTON–(BUSINESS WIRE)–Elucid, Inc., a leading medical technology company providing physicians with AI-powered imaging analysis software to assess cardiovascular disease, today announced that it has named Scott Huennekens executive chairman of its board of directors. “There are few […]
Windtree Therapeutics Announces Closing of $12.42 Million Underwritten Public Offering Including Full Exercise of Overallotment Option
WARRINGTON, Pa., April 24, 2023 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for cardiovascular disorders, today announced the closing of its previously announced underwritten public offering of 3,686,006 shares of common stock, and warrants to purchase up […]



